Vicore Pharma’s holding I-Tech strengthens supply chain with strategic acquisition

Vicore Pharma Holding’s (publ) (ticker: VICO) holding company, I-Tech AB has today announced the acquisition of manufacturing process technology and adherent immaterial property rights, for the production of Selektope® from Cambrex Corporation (NYSE: CBM). The acquisition has been facilitated by the issuing of new shares in I-Tech and Cambrex will after the shares have been registered hold 19,9% of the shares in the company.

Vicore Pharma Holding’s owner share in I-Tech AB will decrease to 21,2% (previous 26,5%) as a consequence of the share issue.

” This is an important deal for I-Tech’s future expansion and continuous growth and we are very pleased that Cambrex, a well-reputed international life-science large-scale manufacturing company will add value as a competent shareholder and Board of directors member in I-Tech.” Says Per Jansson, CEO of Vicore Pharma Holding.

Read the official pressrelease ; https://selektope.com/category/press-releases/  

For more information, please contact:
Per Jansson, CEO, +46 709 17 47 46, per.jansson@vicorepharma.com 

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 10:40 CET on March 13, 2018

About Vicore Pharma Holding
Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and USA. In addition, C21 is explored pre-clinically for a number of diseases where the AT2 receptor plays an important role. I-Tech AB is an associated company to Vicore Pharma Holding. The company has developed and commercialized Selektope® , an effective chemical agent used as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, please refer to www.vicorepharma.com 

About I-Tech
I-Tech is a Gothenburg based bio-tech company with global reach, holding all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). The company is privately held and is supported by Swedish Energy Association, the European Innovation Initiative Eco-Innovation and FP7 SeaFront. The company is a member of the Astra Zeneca BioVentureHub. www.i-tech.se 

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links